Overview

Innoviva (NASDAQ: INVA) is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva’s portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK.

Royalties Earned

chart

Press Releases

Date Title and Summary
Toggle Summary Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion from the CHMP in Europe for Appropriate Patients with COPD
LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for fluticasone
Toggle Summary Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPD
LONDON & BRISBANE, Calif. --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI') as a maintenance
Toggle Summary Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US
LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under the brand name
Toggle Summary Trading in Theravance Common Stock Halted
FDA Advisory Committee to Review ANORO(TM) ELLIPTA(TM) NDA
Presentations & Events
There are currently no events to display.

Copyright Nasdaq. Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.